Central Nervous System Lymphoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Novartis, Kazia Therapeutics, Ono Pharma

Posted on
by

Central Nervous System Lymphoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies - Novartis, Kazia Therapeutics, Ono Pharma
DelveInsight’s “Central Nervous System Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Central Nervous System Lymphoma.

DelveInsight’s “Central Nervous System Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Central Nervous System Lymphoma, historical and forecasted epidemiology as well as the Central Nervous System Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Central Nervous System Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Central Nervous System Lymphoma Market Forecast

 

Some of the key facts of the Central Nervous System Lymphoma Market Report: 

  • The Central Nervous System Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per Lymphoma Action (2021), primary CNSL is very rare, being diagnosed in around 170 patients each year in the UK, primarily affecting men and people over the age of 60
  • According to Lv et al. (2022), the age-adjusted incidence rate of primary CNSL had a fivefold increase, from 0.1/100,000 in 1975 to 0.5/100,000 in 2017, a fivefold increase
  • As per Frank Gaillard et al. (2022), the study reported that primary Central Nervous System Lymphoma are mostly present as solitary, in 60─70% of the cases and as multiple lesions with a predilection for the periventricular white matter, although they can also arise in the cortex or deep grey matter in 30─40% of the cases
  • As per a study conducted by Radke et al. (2021), the occurrence of mutations in primary Central Nervous System Lymphoma in Germany were lead by CDK2NA deletions (83%), followed by MYD88 L265P (67%), and CD79b (63%)
  • Key Central Nervous System Lymphoma Companies: Novartis, Kazia Therapeutics, Ono Pharmaceutical, AstraZeneca, Cellectar Biosciences, Nurix Therapeutics, Sichuan Baili Pharmaceutical, PIQUR Therapeutics AG, Pharmacyclics LLC., Gossamer Bio Inc., Beijing InnoCare Pharma, PentixaPharm GmbH, and others
  • Key Central Nervous System Lymphoma Therapies: Paxalisib, Tirabrutinib, Durvalumab, Iopofosine I 131, NC-5948, GNC-038, PQR309, Ibrutinib, Buparlisib (BKM120), GB5121, ICP-022, 68Ga-PTF, and others
  • The Central Nervous System Lymphoma epidemiology based on gender analyzed that Central Nervous System Lymphoma affects males and females equally
  • The Central Nervous System Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Central Nervous System Lymphoma pipeline products will significantly revolutionize the Central Nervous System Lymphoma market dynamics.

 

Central Nervous System Lymphoma Overview

Central nervous system lymphoma (CNSL) is a rare non-Hodgkin lymphoma, in which malignant cells from lymph tissue forms in the brain, spinal cord, or even the eyes in some cases.

 

Get a Free sample for the Central Nervous System Lymphoma Market Report –

https://www.delveinsight.com/sample-request/central-nervous-system-lymphoma-market

 

Central Nervous System Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Central Nervous System Lymphoma Epidemiology Segmentation:

The Central Nervous System Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Central Nervous System Lymphoma
  • Prevalent Cases of Central Nervous System Lymphoma by severity
  • Gender-specific Prevalence of Central Nervous System Lymphoma
  • Diagnosed Cases of Episodic and Chronic Central Nervous System Lymphoma

 

Download the report to understand which factors are driving Central Nervous System Lymphoma epidemiology trends @ Central Nervous System Lymphoma Epidemiology Forecast

 

Central Nervous System Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Central Nervous System Lymphoma market or expected to get launched during the study period. The analysis covers Central Nervous System Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Central Nervous System Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Central Nervous System Lymphoma Therapies and Key Companies

  • Paxalisib: Kazia Therapeutics
  • Tirabrutinib: Ono Pharmaceutical Co. Ltd
  • Durvalumab: AstraZeneca
  • Iopofosine I 131: Cellectar Biosciences
  • Tirabrutinib: Ono Pharmaceutical
  • NC-5948: Nurix Therapeutics
  • GNC-038: Sichuan Baili Pharmaceutical
  • PQR309: PIQUR Therapeutics AG
  • Ibrutinib: Pharmacyclics LLC.
  • Buparlisib (BKM120): Novartis
  • GB5121: Gossamer Bio Inc.
  • PAXALISIB: Kazia Therapeutics
  • ICP-022: Beijing InnoCare Pharma
  • 68Ga-PTF: PentixaPharm GmbH

 

Discover more about therapies set to grab major Central Nervous System Lymphoma market share @ Central Nervous System Lymphoma Treatment Market

 

Central Nervous System Lymphoma Market Strengths

  • Increasing incidence of Central Nervous System Lymphomas in the 7MM

 

Central Nervous System Lymphoma Market Opportunities

  • Currently, there are no approved therapies, and no widely accepted ‘standard-of-care’ approaches for the treatment of refractory or recurrent primary central nervous system lymphoma (R/R PCNSL)

 

Scope of the Central Nervous System Lymphoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Central Nervous System Lymphoma Companies: Novartis, Kazia Therapeutics, Ono Pharmaceutical, AstraZeneca, Cellectar Biosciences, Nurix Therapeutics, Sichuan Baili Pharmaceutical, PIQUR Therapeutics AG, Pharmacyclics LLC., Gossamer Bio Inc., Beijing InnoCare Pharma, PentixaPharm GmbH, and others
  • Key Central Nervous System Lymphoma Therapies: Paxalisib, Tirabrutinib, Durvalumab, Iopofosine I 131, NC-5948, GNC-038, PQR309, Ibrutinib, Buparlisib (BKM120), GB5121, ICP-022, 68Ga-PTF, and others
  • Central Nervous System Lymphoma Therapeutic Assessment: Central Nervous System Lymphoma current marketed and Central Nervous System Lymphoma emerging therapies
  • Central Nervous System Lymphoma Market Dynamics: Central Nervous System Lymphoma market drivers and Central Nervous System Lymphoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Central Nervous System Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Central Nervous System Lymphoma Market Access and Reimbursement 

 

To know more about Central Nervous System Lymphoma companies working in the treatment market, visit @ Central Nervous System Lymphoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Central Nervous System Lymphoma Market Report Introduction

2. Executive Summary for Central Nervous System Lymphoma

3. SWOT analysis of Central Nervous System Lymphoma

4. Central Nervous System Lymphoma Patient Share (%) Overview at a Glance

5. Central Nervous System Lymphoma Market Overview at a Glance

6. Central Nervous System Lymphoma Disease Background and Overview

7. Central Nervous System Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Central Nervous System Lymphoma 

9. Central Nervous System Lymphoma Current Treatment and Medical Practices

10. Central Nervous System Lymphoma Unmet Needs

11. Central Nervous System Lymphoma Emerging Therapies

12. Central Nervous System Lymphoma Market Outlook

13. Country-Wise Central Nervous System Lymphoma Market Analysis (2019–2032)

14. Central Nervous System Lymphoma Market Access and Reimbursement of Therapies

15. Central Nervous System Lymphoma Market Drivers

16. Central Nervous System Lymphoma Market Barriers

17.  Central Nervous System Lymphoma Appendix

18. Central Nervous System Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services